Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer

Buffalo, NY and Hong Kong – March 28, 2017 -- Athenex, Inc., a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies, announced...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials